Sökning: "Multidrug-resistant"

Visar resultat 1 - 5 av 68 avhandlingar innehållade ordet Multidrug-resistant.

  1. 1. β-lactam combinations against multidrug-resistant Enterobacterales : Exploring combination effects and resistance development

    Författare :Lisa Allander; Thomas Tängdén; Linus Sandegren; Pernilla Lagerbäck; Arnfinn Sundsfjord; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Gram-negative bacteria; antibiotic combination therapy; antibiotic resistance; beta-lactams; beta-lactamase inhibitors; Infektionssjukdomar; Infectious Diseases;

    Sammanfattning : The β-lactam antibiotics are a cornerstone in treating bacterial infections, but the increasing prevalence of antibiotic resistance worldwide threatens their effectiveness. The main driver of β-lactam resistance is the production of β-lactamases, which are bacterial enzymes that inactivate the antibiotic. LÄS MER

  3. 2. Treatment optimisation of multidrug-resistant tuberculosis

    Författare :Johanna Kuhlin; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : A successful treatment outcome is seen in only 60% of persons treated for multidrugresistant tuberculosis (MDR-TB) worldwide, defined as resistance to both rifampicin and isoniazid. To improve these disturbingly low numbers, treatment optimisation is highly needed. LÄS MER

  4. 3. Multidrug-Resistant Escherichia coli and Klebsiella pneumoniae : Treatment, Selection and International Spread

    Författare :Thomas Tängdén; Otto Cars; Anders Johansson; Uppsala universitet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Escherichia coli; Klebsiella pneumoniae; extended-spectrum beta-lactamases; carbapenemases; metallo-beta-lactamases; synergy; antibiotic interventions;

    Sammanfattning : The prevalence of Escherichia coli and Klebsiella pneumoniae producing extended-spectrum beta-lactamases (ESBLs) and carbapenemases is increasing worldwide. Therapeutic options for infections with these bacteria are limited not only by the production of ESBLs and carbapenemases, which confer resistance to cephalosporins and carbapenems, but also by frequent co-resistance to other antibiotics. LÄS MER

  5. 4. Novel treatment strategies for multidrug-resistant tuberculosis

    Författare :Lina Davies Forsman; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Tuberculosis is the leading cause of death from a single infectious agent in the world, surpassing the annual death toll of both malaria and HIV combined. The rise in multidrug-resistant tuberculosis (MDR-TB) has further exacerbated the situation, as this form of TB is more difficult and time-consuming to treat, with dismal cure rates. LÄS MER

  7. 5. Interactions between innate immune effectors and multidrug resistant bacteria

    Författare :Harpa Káradóttir; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Antibiotic resistance is an increasingly difficult problem in the clinic, where conventional antibiotics are failing, and new alternative solutions are in high demand. Infections caused by Gram-negative bacteria with multi drug resistance (MDR) mechanisms are increasing globally, and treatment options are limited. LÄS MER